Ticker	Current Price	Change	Graph
IBB	108.17	3.8 (3.39%)
XBI	87.86	4.06 (4.42%)

M&A, People

Chastened Allergan chief Brent Saunders bows to activists, agreeing to a separate chairman's role (later), new M&A committee and a big pay cut

M&A, R&D

UPDATED: Is a severely damaged Biogen looking to shed its ties to a controversial development partner?

M&A

Thermo Fisher forges $1.7 billion deal to buy a contract player in the booming gene therapy field

Latest

FDA snubs Sanofi, Lexicon on their pitch for SGLT1/2 diabetes drug sotagliflozin, companies mum on what went wrong →

Hacking into macrophage attack circuits, Stanford scientists pitch a better early-warning alert system for tumors →

Bone-marrow focused Imago BioSciences scores $40M in Omega-led round →

After landing a historic FDA OK, Alnylam chief John Maraganore scores a big raise →

Little Conatus' Novartis-partnered liver drug suffers third straight defeat, but CEO Mento is still holding out hope →

J&J mops up $900M in waste, writing off the last big chunk of the $1.75B it spent to acquire Alios →

Shanghai-based cancer drugmaker Abbisko lines up $42M B round as it makes a leap for the clinic →

Hard-charging GSK research chief Hal Barron touts improved anti-BCMA data, aiming for fast applications →

$757M and 5 years later, Celgene abandoned a biotech partner, triggering layoffs →

Founding Forma CEO Steve Tregay follows 61 staffers out the exit, replaced by Genentech strategy vet →

UPDATED: Feng Zhang, heavyweight collaborators unveil latest CRISPR upstart — a diagnostic company →

Brexit who? Record investment last year fuels big spike in registered UK biotech firms →

Top News

RIP amyloid beta theory? Nope. Biogen partner launches a new PhIII before aducanumab's corpse turned cold

John Carroll

Billionaire Bertarelli's Waypoint steers allergy drugmaker Stallergenes Greer private in $832M buyout deal

Natalie Grover

UPDATED: Biogen's Alzheimer's drug aducanumab implodes in a PhIII disaster — putting them at a perilous crossroads

John Carroll

Faster, cheaper, better? Post-buyout deal Celgene jumps into AI alliance with a $25 million bet on speeding discovery work

John Carroll

With eye on revenue stabilization, Gilead takes 4.9% hike on a basket of drugs

Natalie Grover

More news

Protocols

Quick hits from around the biopharma web

Mar 22

Novartis' Alcon unit set for Swiss/NYSE debut on April 9; Novo's keenly anticipated oral GLP-1 submitted for speedy US review

Mar 21

Roivant's rare disease shop captures FDA designations; China biotech lands $18M launch round

Mar 20

To tackle soaring prescription drug costs, Canada creates new agency to negotiate prices; DMC clears phIII testing of Cytokinetics' Amgen-partnered heart drug

Mar 19

Affimed lands milestone from Roche; Puma touts new PHII data on cervical cancer

More Protocols

Peer Review

Weekly biopharma careers news report

Mar 22

Entrada picks Syntimmune vet Mario Saltarello as CMO; Gene therapy maker Orchard hires Ran Zheng as CTO

Mar 15

AstraZeneca vet Jennifer Butler takes charge of Innate Pharma's US biz; C4 raids NIBR

Mar 8

From Agios to Deciphera, Steve Hoerter plots another oncology launch; Roche exec Christiane Hamachar moves to India as CEO of Biocon Biologics

Mar 1

ReViral taps Seth Hetherington to guide upcoming PhIIa; Incyte, Aquinox execs move to AI shop Notable Labs

More peer review

Premium

Team building. Pipeline revamp. Forward thrust. What does a decade of deals at Gilead tell us about Daniel O’Day’s first M&A moves?

After a slate of small, tack-on acquisitions, is Merck ready to pull the trigger on a big M&A deal?

By the numbers: Top M&A deals, VC investments and pacts point to a growing hunger for gene therapy deals

The $100M biotech club: Who's in, and what’s it take to join the top-performing group of biopharmas?

The high rollers: The top 20 blockbuster biopharma deals of the past decade

Top 20 biotech deals: 2019 dealmaking gets off to a roaring start, building on a record amount for '18

AstraZeneca CEO Soriot is overseeing a top exec team overhaul in move to integrate MedImmune in a sweeping restructuring

Path to the top: What kind of experience does it take to get tapped for the helm of a biotech?

By the numbers for 2018: The top 100 venture players in biotech — and who's been paying the piper in cancer R&D?

Bioregnum

The view from John Carroll

Mar 22

RIP amyloid beta theory? Nope. Biogen partner launches a new PhIII before aducanumab's corpse turned cold

Mar 7

How do you replace a rock star like Scott Gottlieb at the FDA? Maybe you can't

Jan 29

As Pfizer kills failed PhIII programs for Bavencio, where do they go from here in R&D?

Jan 25

The antibiotics R&D effort is broken. Here's one market solution that might fix it

More opinion

Marco

Top biopharma links on Twitter - last updated ago

Most Viral

TransConTM Growth Hormone in the Treatment of Pediatric Growth Hormone Deficiency

Gcs-web a day

Lilly discloses pricing data on insulin in response to political pressure - STAT

STAT a day

Thermo Fisher to Buy Brammer Bio for $1.7 Billion

WSJ a day

A case against a moratorium on germline gene editing

The Conversation G. Owen Schaefer a day

An Alzheimer's Drug Trial Gave Me Hope, and Then It Ended

New York Times a day

Medicare for All Would Abolish Private Insurance. 'There's No Precedent in American History.'

New York Times Reed Abelson a day

The Guardian view on statistics in sciences: gaming the (un)known | Editorial

The Guardian Editorial a day

Why 'Medicare For All' Plays Well In Trump Country

Forbes a day

Latest

New York Times

Medicare for All Would Abolish Private Insurance. 'There's No Precedent in American History.'

Gcs-web

TransConTM Growth Hormone in the Treatment of Pediatric Growth Hormone Deficiency

The Guardian

The Guardian view on statistics in sciences: gaming the (un)known | Editorial

STAT

Lilly discloses pricing data on insulin in response to political pressure - STAT

WSJ

Thermo Fisher to Buy Brammer Bio for $1.7 Billion

New York Times

An Alzheimer's Drug Trial Gave Me Hope, and Then It Ended

The Conversation

A case against a moratorium on germline gene editing

Forbes

Why 'Medicare For All' Plays Well In Trump Country

JAMA

Practical Suggestions for Obesity Management in Clinical Practice

The BMJ

Data sharing practices of medicines related apps and the mobile ecosystem: traffic, content, and network analysis

Hot This Week

1

STAT

Amarin's Vascepa prevents second and third heart attacks in analysis

2

Kaiser Health News

Death By A Thousand Clicks

3

STAT

Alzheimer's drug failure leaves Biogen in a precarious place - STAT

4

STAT

Biogen halts study of Alzheimer's drug, a blow to hopes for new treatment

5

Forbes

How Will The Failure Of Biogen's Alzheimer's Drug, Aducanumab, Impact R&D?

6

ENDPOINTS NEWS

Vivek Ramaswamy's Urovant claims a big win in PhIII - but questions linger about the cheap generic comparator

7

FDA

FDA approves first treatment for post-partum depression

8

BusinessWire

Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics

9

Evaluate.com

Celyad spells out its off-the-shelf ambitions

10

Evaluate.com

Chastened Allergan chief Brent Saunders bows to activists, agreeing to a separate chairman's role (later), new M&A committee and a big pay cut

UPDATED: Is a severely damaged Biogen looking to shed its ties to a controversial development partner?

Thermo Fisher forges $1.7 billion deal to buy a contract player in the booming gene therapy field

Latest

FDA snubs Sanofi, Lexicon on their pitch for SGLT1/2 diabetes drug sotagliflozin, companies mum on what went wrong →

Hacking into macrophage attack circuits, Stanford scientists pitch a better early-warning alert system for tumors →

Bone-marrow focused Imago BioSciences scores $40M in Omega-led round →

After landing a historic FDA OK, Alnylam chief John Maraganore scores a big raise →

Little Conatus' Novartis-partnered liver drug suffers third straight defeat, but CEO Mento is still holding out hope →

J&J mops up $900M in waste, writing off the last big chunk of the $1.75B it spent to acquire Alios →

Shanghai-based cancer drugmaker Abbisko lines up $42M B round as it makes a leap for the clinic →

Hard-charging GSK research chief Hal Barron touts improved anti-BCMA data, aiming for fast applications →

$757M and 5 years later, Celgene abandoned a biotech partner, triggering layoffs →

Founding Forma CEO Steve Tregay follows 61 staffers out the exit, replaced by Genentech strategy vet →

UPDATED: Feng Zhang, heavyweight collaborators unveil latest CRISPR upstart — a diagnostic company →

Brexit who? Record investment last year fuels big spike in registered UK biotech firms →

Sponsored

Top News

Protocols

Peer Review

Premium

Team building. Pipeline revamp. Forward thrust. What does a decade of deals at Gilead tell us about Daniel O’Day’s first M&A moves?

After a slate of small, tack-on acquisitions, is Merck ready to pull the trigger on a big M&A deal?

By the numbers: Top M&A deals, VC investments and pacts point to a growing hunger for gene therapy deals

The $100M biotech club: Who's in, and what’s it take to join the top-performing group of biopharmas?

The high rollers: The top 20 blockbuster biopharma deals of the past decade

Top 20 biotech deals: 2019 dealmaking gets off to a roaring start, building on a record amount for '18

AstraZeneca CEO Soriot is overseeing a top exec team overhaul in move to integrate MedImmune in a sweeping restructuring

Path to the top: What kind of experience does it take to get tapped for the helm of a biotech?

By the numbers for 2018: The top 100 venture players in biotech — and who's been paying the piper in cancer R&D?

Bioregnum

Most Viral

Latest

Hot This Week

Contact Endpoints News

Sign in to Endpoints News

Request a magic link

Set a new password